Anika Therapeutics, Inc. 10-Q filing
Filed 2026-04-30 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001171843-26-002852
- Form type
- 10-Q
- CIK
- 0000898437
- Primary document
- https://www.sec.gov/Archives/edgar/data/898437/000117184326002852/anik20260331_10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Anika Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $29.6M | - | - |
| Cost Of Revenue | $10.6M | - | - |
| Gross Profit | $19.0M | - | - |
| Operating Income | $-5.5M | - | - |
| Net Income | $-5.1M | - | - |
| Eps Basic | -0.37 | - | - |
| Eps Diluted | -0.37 | - | - |
| Cash And Equivalents | $41.0M | - | - |
| Total Assets | $179.4M | - | - |
| Shareholders Equity | $133.9M | - | - |
| Operating Cash Flow | $-4.8M | - | - |
| Capital Expenditures | $1.4M | - | - |